Cart
Orders
Not available hereProduct Overview
Saxenda is a prescription weight-management medicine containing liraglutide 6 mg/mL as a solution for injection in a pre-filled pen. Each 3 mL pen contains 18 mg of liraglutide. Novo Nordisk A/S is the EU marketing authorization holder. Saxenda is used alongside dietary and physical-activity measures in eligible patients. For professional product assessment, key specifications include the pen content, market-specific carton configuration and applicable prescribing information.
Prescribing eligibility and purchasing restrictions depend on the destination jurisdiction. This listing does not establish permission to purchase or supply Saxenda in any particular market.
Key Features
- Defined concentration: Each milliliter contains 6 mg of liraglutide.
- Pre-filled presentation: A disposable multidose pen contains 3 mL of injectable solution.
- Documented one-pen pack: Korean labeling includes a carton containing one 3 mL pre-filled pen; confirm the supplied market pack before procurement.
Composition & Specifications
| Specification | Product information |
|---|---|
| Product name | Saxenda 6 mg/mL solution for injection in pre-filled pen |
| Product category | Prescription weight-management medicine |
| Active ingredient | Liraglutide 6 mg/mL |
| Content per pen | 3 mL solution containing 18 mg liraglutide |
| Formulation | Clear, colourless or almost colourless solution in a disposable multidose pre-filled pen |
| EU authorization holder | Novo Nordisk A/S |
| Documented one-pen presentation | One 3 mL pre-filled pen per carton in Korean labeling; supplied carton requires confirmation |
| Finished-product country of origin | Not publicly verified for the supplied pack |
How Liraglutide Works
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It acts on appetite-regulating pathways, helping reduce hunger and food intake. This mechanism does not guarantee an individual weight-loss result. Saxenda is not an insulin replacement, and its weight-management indication should not be confused with a general diabetes-treatment indication.
Storage & Handling
Korean labeling specifies refrigeration at 2–8°C, protection from light and no freezing. After opening, that labeling permits storage for up to one month at 30°C or below, or under refrigeration.
Follow the instructions and expiry date on the actual supplied market pack. In-use storage wording differs between markets; the Korean conditions above should not replace another market's labeling.
Frequently Asked Questions
Does 18 mg per pen mean a concentration of 18 mg/mL?
No. Saxenda contains 6 mg/mL. The 18 mg figure is the total liraglutide content of the 3 mL pen, not the concentration or an administration recommendation.
What should professional buyers confirm about the pack?
Confirm the original carton, market authorization identifier, barcode, batch details and expiry date. A one-pen carton is documented in Korean labeling, but the supplied pack's market identity and manufacturing country require pack-specific confirmation.
Are prescribing requirements identical across countries?
No. Approved eligibility criteria differ by jurisdiction. Review the applicable prescribing information, contraindications and warnings. US labeling includes a boxed warning concerning thyroid C-cell tumors; this page is not a substitute for the complete local prescribing information.